MARY PONDER: Open Payments
NPI 1396288197 · FLOWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$779 in 52 payments from 15 companies in 2025. Trend: 2023 $971 · 2024 $396 · 2025 $779
Food & beverage: $779
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $207 |
| Lilly USA, LLC | 11 | $157 |
| PFIZER INC. | 4 | $67 |
| Amgen Inc. | 3 | $52 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $52 |
| Novo Nordisk Inc | 3 | $51 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Eisai Inc. | 1 | $21 |
| Abbott Laboratories | 1 | $21 |
Products named: MOUNJARO, UBRELVY, QULIPTA, VRAYLAR, CAPLYTA, NURTEC ODT, FARXIGA, OTEZLA.
Industry payments across MS — which companies pay providers there.
